Ucb Is A Global Biopharmaceutical Company Based In Brusselsbelgiumwith U Soperations In Atlantageorgiafounded In 1928Ucb Initially Focused On Industrial Chemicals Before Shifting Its Emphasis To Pharmaceuticalsthe Company Develops Innovative Therapies Primarily In The Fields Of Immunology And Neurologyserving Over 3 7 Million Patients Worldwide Ucb S Product Portfolio Includes Treatments For Severe Diseasesin Neurologyit Offers Antiepileptic Drugs Like Keppra And Vimpatas Well As Fenfluramine For Lennox Gastaut Syndromein Immunologyucb Provides Cimzia For Autoimmune Conditions And Bimzelx For Plaque Psoriasisthe Company Also Markets Antihistamines Such As Zyrtec And Xyzalucb Has Expanded Its Capabilities Through Strategic Acquisitionsincluding Ra Pharma And Zogenixenhancing Its Focus On Rare Diseases And Biologics With A Revenue Of A 5 78 Billion In 2021 And A Commitment To Research And Developmentucb Continues To Prioritize Patient Centric Innovation Across North Americaeuropeand Asia Pacific
No conferences found for this company.
| Company Name | Ucb Canada Inc |
| Country |
Canada
|
| Address | N/A |
| Telephone | N/A |
| N/A |
